TB-500
5mg
TB-500 is a synthetic fragment of thymosin beta-4, a protein present in virtually all human and animal cells. Research has focused on its role in cell migration, blood vessel formation and cell differentiation. TB-500 contains the active region of thymosin beta-4 responsible for actin binding and cell motility, making it one of the most referenced compounds in cell biology and wound healing research. Often studied alongside BPC-157. Supplied as lyophilised powder, third-party tested, lab certificate published on this page.
Published research on TB-500 is indexed on PubMed. See our full UK buyer's guide for Research Peptides.
Intended Use: Strictly for in-vitro laboratory research. Not for use in humans or animals. Not to be used in foods, drugs, or medical diagnostics. This product has not been evaluated by the MHRA or FDA. Buyer assumes full responsibility for safe handling and regulatory compliance.
≥98%
Purity
LAB
Certified
SAME
Day Ship
Quantity
Add £21.01 more for free UK delivery
Damaged or lost? Free reshipment guaranteed
BPC-157 + TB-500 5+5mg
Pre-blended soft-tissue research peptide vial. BPC-157 and TB-500 combined.
All components in a single lyophilised vial. One reconstitution, one inventory line, one CoA.
Research Use Only
This product is intended strictly for research and laboratory use only. Not for human consumption, medical use, or diagnostic purposes.
Certificate of Analysis
Third-party tested
Lyophilised Stability
24 months
Sealed at -20°C, light-protected
Reconstituted Stability
Up to 3 months
Stored at 2-8°C after mixing
Cold-Chain Shipping
Always
Dry-cold pack, Royal Mail Tracked 24
Important Notice
All compounds are sold individually and do not include research supplies. Products are provided in lyophilised (powder) form and require proper reconstitution before use in research settings.
Related Products
TB-500 Price (UK)
TB-500 5mg is £23.99 per vial, supplied from stock in the UK with a third-party HPLC certificate published on this page. UK delivery is £4.50 by Royal Mail Tracked 24, or free once your basket reaches £45 (£21.01 away at this price). Orders placed before 2pm on a working day are dispatched the same day.
| Vial | Price | Cost per mg | Availability |
|---|---|---|---|
| TB-500 5mgThis page | £23.99 | £4.80 | In stock |
Prices are in GBP and shown per vial as supplied, lyophilised, for in-vitro laboratory research only. Cost per mg is given so researchers can compare vial sizes on a like-for-like basis. Stock and pricing on this table are read live from our inventory, so they match the basket. See our FAQ for delivery and payment options, and quality & testing for how each batch is verified.
Product Specifications
Research Overview
TB-500 is the research-market designation for synthetic thymosin beta 4 (Tβ4), a 43-residue, N-terminally acetylated polypeptide with molecular formula C₂₁₂H₃₅₀N₅₆O₇₈S, molecular weight 4963.4 g/mol and CAS number 77591-33-4. Tβ4 is the most abundant member of the beta-thymosin family in mammalian tissue and the principal G-actin sequestering molecule in eukaryotic cells, present in blood platelets, wound fluid and essentially all nucleated cells. Nomenclature is worth stating precisely, because the name TB-500 has been applied to two chemically different things. Ho and colleagues (J Chromatogr A, 2012), developing doping-control assays, characterised a veterinary preparation sold as TB-500 that contained only the heptapeptide LKKTETQ, the actin-binding active site spanning residues 17 to 23 of Tβ4. Material supplied here is the full 43-residue acetylated sequence, confirmed by mass spectrometry at 4964.4 for the singly protonated ion on the published certificate of analysis. The actin-binding motif is the functional core of the molecule. Philp and colleagues (FASEB J, 2003) showed the LKKTETQ site alone is sufficient to promote endothelial cell migration and angiogenesis in aortic ring and chick chorioallantoic assays, and Sosne and colleagues (FASEB J, 2010) mapped further activities onto short internal sequences of the parent protein. Beyond simple actin sequestration, Bock-Marquette and colleagues reported in Nature (2004) that Tβ4 activates integrin-linked kinase and Akt, promoting cardiomyocyte and epicardial cell migration and survival in mouse cardiac injury models, which established a signalling role separate from cytoskeletal buffering. Thymosin beta 4 is also one of few compounds in this class with genuine randomised controlled human data, though in a topical ophthalmic formulation rather than a systemic one, RGN-259 eye drops having been evaluated in placebo-controlled Phase 2 and Phase 3 trials (Sosne et al., Cornea 2015 and Int J Mol Sci 2023). TB500 is supplied as lyophilised powder for in vitro and laboratory research use only.
Product Specifications
Laboratory Handling
- Store lyophilised vials at -20°C, protected from light and moisture. Reconstituted TB-500 should be held at 2-8°C.
- Reconstitute with bacteriostatic water directed slowly down the inner glass wall. Swirl gently until dissolved, never vortex, the 43-residue chain is shear sensitive.
- Maintain aseptic technique throughout. Sterilise the vial stopper with 70% isopropyl alcohol before every needle insertion.
- Aliquot reconstituted stock into single-use volumes and avoid repeated freeze-thaw cycles, which reduce recovery of intact peptide.
Frequently Asked Questions
What is TB-500?
TB-500, also written TB500, is the research-market designation for synthetic thymosin beta 4 (Tβ4), a 43-residue N-terminally acetylated polypeptide, sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES, molecular formula C₂₁₂H₃₅₀N₅₆O₇₈S, molecular weight 4963.4 g/mol, CAS 77591-33-4. Thymosin beta 4 is the most abundant beta-thymosin in mammalian tissue and the principal G-actin sequestering molecule in eukaryotic cells, present in blood platelets, wound fluid and essentially all nucleated cells. Its actin-binding active site is the heptapeptide LKKTETQ at residues 17 to 23. Note that the TB-500 name has historically been applied both to the full 43-residue protein and, as documented by Ho and colleagues (J Chromatogr A, 2012), to preparations containing only the LKKTETQ heptapeptide. Material supplied here is the full 43-residue sequence, evidenced by a mass spectrometry result of 4964.4 for the singly protonated ion on the published certificate of analysis. Supplied as lyophilised powder for in-vitro research use only, not a licensed medicine.
TB-500 vs BPC-157
TB-500 and BPC-157 differ in size, origin and mechanism. TB-500 is a 43-residue, 4963.4 g/mol thymosin beta 4 sequence that sequesters monomeric G-actin and thereby regulates cytoskeletal dynamics and cell motility. Philp and colleagues (FASEB J, 2003) showed the LKKTETQ actin-binding site alone is sufficient to promote endothelial cell migration and angiogenesis, and Bock-Marquette and colleagues (Nature, 2004) reported activation of integrin-linked kinase and Akt with cardiomyocyte and epicardial cell migration in mouse cardiac injury models, indicating a signalling role separate from actin buffering. BPC-157 is a 15-residue, 1419.53 g/mol pentadecapeptide from human gastric juice whose literature centres on local angiogenic signalling via VEGFR2 and on nitric oxide pathway modulation. Choose TB-500 when actin dynamics, systemic cell migration, cardiac or corneal models are the endpoint, and BPC-157 for gastric mucosal or localised tendon and ligament work.
TB-500 Research Applications
TB-500 is studied in models of cardiac repair after ischaemic injury, dermal and burn wound closure, corneal epithelial repair, skeletal muscle regeneration and myoblast chemotaxis, hair follicle biology, and inflammatory cytokine modulation. Reported cellular endpoints include endothelial and keratinocyte migration, collagen deposition, integrin-linked kinase and Akt activation, and HIF-1 alpha interaction in migration assays. Thymosin beta 4 is unusual in this compound class for having controlled human data, RGN-259 ophthalmic solution has been assessed in randomised, placebo-controlled, double-masked Phase 2 and Phase 3 trials in severe dry eye and neurotrophic keratopathy (Sosne et al., Cornea 2015 and Int J Mol Sci 2023). That record applies to a topical ocular formulation only, other routes and endpoints remain preclinical.
Reconstitution Guide
Allow vials to reach room temperature, then sterilise the rubber stopper of both the peptide vial and the bacteriostatic water vial with an alcohol swab. Slowly draw your bacteriostatic water into a sterile insulin syringe, then inject it gently down the inner glass wall of the peptide vial, never directly onto the lyophilised powder. Once added, gently swirl the vial in a slow circular motion until fully dissolved. Never shake or vortex, a 43-residue chain is shear sensitive and agitation reduces recovery of intact peptide. The solution should be clear and colourless. Label the vial with the reconstitution date and store immediately.
See our full peptide reconstitution guide and reconstitution calculator for step-by-step protocol.
Storage Instructions
Lyophilised vials should be stored at -20°C, protected from light and moisture, and remain stable for up to 24 months. Once reconstituted with bacteriostatic water, store the solution at 2-8°C (standard refrigerator) and use within approximately 3 months. For storage beyond that, prepare single-use aliquots at -20°C, where reconstituted peptide remains stable for up to 6 months. Avoid repeated freeze-thaw cycles and always handle under sterile laboratory conditions.
Frequently Asked Questions
Research References
- Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Bock-Marquette et al., Nature, 2004)
- The actin binding site on thymosin beta4 promotes angiogenesis (Philp et al., FASEB J, 2003)
- Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta 4 (Ho et al., J Chromatogr A, 2012)
Related Research Compounds
TB-500
5mg · £23.99